International Edition
Latest News
Health

Melanoma Protein Patterns Predict Immunotherapy Response, Survival

"Protein atlases bridge the gap between genomic possibility and therapeutic reality," said Diwakar Davar, associate professor of medicine at the University of Pittsburgh and co-leader of the Cancer Immunology and Immunotherapy Program at UPMC Hillman Cancer Center. Two…

Melanoma Protein Patterns Predict Immunotherapy Response, Survival

“Protein atlases bridge the gap between genomic possibility and therapeutic reality,” said Diwakar Davar, associate professor of medicine at the University of Pittsburgh and co-leader of the Cancer Immunology and Immunotherapy Program at UPMC Hillman Cancer Center.

Two companion studies published Nov. 17 in Cancer Discovery and Clinical Cancer Research identified three protein patterns in melanoma tumors that predict response to combination immunotherapy and mapped a comprehensive molecular atlas of the disease, according to reports from the University of Pittsburgh and the Icahn School of Medicine at Mount Sinai.

The findings address a persistent clinical problem: immune checkpoint inhibitors have improved melanoma survival over the past 15 years, yet 40 to 60 percent of patients either do not respond or eventually develop resistance, Davar told Medical Xpress. Current biomarkers that reliably predict who will benefit remain elusive.

Researchers from the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) analyzed pretreatment tumor samples to understand the biological differences driving those outcomes. The Clinical Cancer Research study examined 207 patients with metastatic cutaneous melanoma treated at 12 institutions; 164 received combination PD-1 and CTLA-4 blockade and the remainder received PD-1 monotherapy, News-Medical reported.

The Cancer Discovery study profiled 183 tumors across 13 molecular layers — including genomics, proteomics, metabolomics, immunopeptidomics, ubiquitylomics and glycoproteomics — to build a multi-omic atlas of tumor immunogenicity.

Melanoma Protein Patterns Predict Immunotherapy Response, Survival
Photo: eurekalert.org

Three proteomic subtypes tied to distinct outcomes

The Clinical Cancer Research team identified three proteomic subtypes. One showed high immune activity, a second was enriched for ribosomal proteins and cell proliferation signals, and a third carried features of the tumor microenvironment associated with growth and metastasis, according to EurekAlert and Mirage News.

Patients whose tumors fell into the immune-rich subtype had the most favorable progression-free survival after combination immunotherapy. The other two subtypes fared worse but differed molecularly, suggesting they may require different therapeutic strategies, said Pei Wang, professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai and lead contact author of the Cancer Discovery study.

Shrabanti Chowdhury, assistant professor of genetics and genomic sciences at Icahn Mount Sinai and lead first author of the Clinical Cancer Research paper, said the team developed a classifier that assigns tumors to these three groups based on a panel of 127 proteins. The tool was independently validated in two patient cohorts and predicted treatment response and progression-free survival with high certainty, Medical Xpress and EurekAlert reported.

Melanoma Protein Patterns Predict Immunotherapy Response, Survival
Photo: miragenews.com

Atlas uncovers 1,000 tumor antigens

The Cancer Discovery atlas uncovered more than 1,000 candidate tumor antigens — protein fragments displayed on cell surfaces for immune recognition — that warrant further testing as immunotherapy targets, the Mount Sinai release stated. Mass spectrometry-based HLA-I immunopeptidomics showed a correlation between these antigens and CD8+ T-cell infiltration.

Chemical modifications to proteins provided survival links that protein abundance alone did not capture. Ubiquitylation of the interferon signaling pathway marked a subset of tumors with worse survival and was tied to AKT1 activation. Glycosylation of the protein GPNMB emerged as a feature associated with sex-specific survival, pointing to potential differences in immunotherapy response between men and women.

Metabolomic profiling distinguished ether-linked lipids and mitochondrial metabolic profiles between primary and metastatic tumors, adding another layer to the tumor microenvironment portrait.

From association to clinical test

Both studies establish associations, not causation, and the authors caution that larger prospective studies in more diverse populations are needed before clinical use.

“Our next step is to translate these findings into a practical clinical test,” said Amanda Paulovich, principal investigator at Fred Hutchinson Cancer Center and co-principal investigator of the CPTAC Proteogenomic Translational Research Center that led the Clinical Cancer Research study. Her laboratory aims to develop a targeted mass spectrometry assay that can reliably classify individual patients’ tumors using routine biopsy samples.

The research was supported by the National Cancer Institute, including CPTAC and all NCI-funded Melanoma SPORE programs, with additional funding from the Aven Foundation for Paulovich’s lab. Tao Liu of Pacific Northwest National Laboratory and Marcin Cieslik of the University of Michigan served as collaborating principal investigators.

“We’ve identified a panel of 127 proteins that can distinguish among three melanoma subtypes associated with different responses to immunotherapy,” Paulovich said. “Ultimately, our goal is to give oncologists better tools to predict which patients are most likely to benefit from a particular treatment — and which patients may need a different approach.”

About the author: Health Desk

Health Desk at Archynewsy.